In honor of Asthma Awareness Month, Pulmonology Advisor interviewed David A. Hill, MD, of the American Lung Association, to highlight the advances in care as well as gaps in knowledge and treatment.
The prevalence of asthma-COPD overlap is highly variable, depending on the definition used at the time of diagnosis.
When used as needed, the combination of budesonide-formoterol was found to be superior to albuterol for the prevention of asthma exacerbations in patients with mild asthma.
Patients with corticosteroid-dependent severe asthma who received dupilumab had better asthma control and health-related quality of life compared with those who received placebo.
Researchers compared lung function improvements within the combination subgroups of high/low eosinophil levels and high/low FEV1 reversibility in patients with moderate to severe asthma treated with omalizumab vs patients who took placebo.
Benralizumab has been found to be associated with a reduction in oral corticosteroid (OCS) use while maintaining asthma control for patients with OCS-dependent severe asthma.
Investigators sought to determine a link between baseline blood eosinophil counts and certain biomarkers and observed that mepolizumab-treated individuals with elevated baseline levels of eosinophil-derived neurotoxin experienced the greatest reduction in exacerbation rates.
The study was designed to examine the prescribing patterns at a large academic teaching center to identify patients who have taken more than one biologic asthma medication, either sequentially or simultaneously, and to analyze the outcomes.
Investigators examined the effectiveness of low-dose beclomethasone/formoterol maintenance and reliever therapy vs beclomethasone/formoterol plus salbutamol to lower the exacerbation rate in patients with moderate to acute asthma.
The creation of a novel pediatric-automated respiratory score is a feasible option to standardize pediatric intensive care unit management of patients with acute asthma exacerbations.
